A detailed history of Ameritas Investment Partners, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 16,509 shares of VRTX stock, worth $7.74 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
16,509
Previous 16,615 0.64%
Holding current value
$7.74 Million
Previous $6.76 Million 2.07%
% of portfolio
0.24%
Previous 0.25%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$407.69 - $446.08 $43,215 - $47,284
-106 Reduced 0.64%
16,509 $6.9 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $30,184 - $36,139
-88 Reduced 0.53%
16,615 $6.76 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $289,482 - $310,265
856 Added 5.4%
16,703 $5.81 Million
Q2 2023

Aug 11, 2023

SELL
$314.42 - $351.91 $210,975 - $236,131
-671 Reduced 4.06%
15,847 $5.58 Million
Q1 2023

May 10, 2023

BUY
$283.23 - $323.1 $7,363 - $8,400
26 Added 0.16%
16,518 $5.2 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $166,598 - $187,422
-583 Reduced 3.41%
16,492 $4.76 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $62,707 - $69,966
-229 Reduced 1.32%
17,075 $4.94 Million
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $469 - $585
-2 Reduced 0.01%
17,304 $4.87 Million
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $33,434 - $39,406
-151 Reduced 0.86%
17,306 $4.52 Million
Q4 2021

Feb 11, 2022

SELL
$177.01 - $223.45 $44,606 - $56,309
-252 Reduced 1.42%
17,457 $3.83 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $29,203 - $32,681
161 Added 0.92%
17,709 $3.21 Million
Q2 2021

Aug 06, 2021

SELL
$187.49 - $221.1 $14,249 - $16,803
-76 Reduced 0.43%
17,548 $3.54 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $13,249 - $15,443
-64 Reduced 0.36%
17,624 $3.9 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $29,395 - $39,204
-142 Reduced 0.8%
17,688 $4.18 Million
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $105,072 - $124,574
-411 Reduced 2.25%
17,830 $4.85 Million
Q2 2020

Aug 05, 2020

SELL
$225.48 - $295.8 $1,803 - $2,366
-8 Reduced 0.04%
18,241 $5.3 Million
Q1 2020

May 13, 2020

SELL
$199.77 - $247.81 $289,466 - $359,076
-1,449 Reduced 7.36%
18,249 $4.34 Million
Q4 2019

Feb 13, 2020

BUY
$166.71 - $223.91 $426,610 - $572,985
2,559 Added 14.93%
19,698 $4.31 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $1.3 Million - $1.47 Million
7,849 Added 84.49%
17,139 $2.9 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $10,370 - $11,993
-63 Reduced 0.67%
9,290 $1.7 Million
Q1 2019

May 15, 2019

BUY
$163.73 - $194.7 $17,682 - $21,027
108 Added 1.17%
9,353 $1.72 Million
Q4 2018

Feb 12, 2019

BUY
$151.91 - $192.21 $10,177 - $12,878
67 Added 0.73%
9,245 $1.53 Million
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $44,448 - $51,076
-265 Reduced 2.81%
9,178 $1.77 Million
Q2 2018

Aug 13, 2018

SELL
$145.72 - $169.96 $50,564 - $58,976
-347 Reduced 3.54%
9,443 $1.6 Million
Q1 2018

May 15, 2018

SELL
$151.6 - $177.13 $44,873 - $52,430
-296 Reduced 2.93%
9,790 $1.6 Million
Q4 2017

Feb 14, 2018

SELL
$137.28 - $155.55 $10,707 - $12,132
-78 Reduced 0.77%
10,086 $1.51 Million
Q2 2017

Aug 15, 2017

BUY
N/A
10,164
10,164 $1.31 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.